Topic:

Drug Safety

Latest Headlines

Latest Headlines

American-made jerky treats linked to kidney illness in dogs

Despite efforts by major pet retailers to remove China-made jerky treats for pets from stores--moves that were made following an outbreak of a rare kidney disease in dogs called Fanconi, which was tied to chicken jerky--the illness is still being reported.

Takeda offers $2.2B to settle Actos cases, sources tell Bloomberg

Takeda lost its very first jury trial in 2013 over claims that it didn't sufficiently warn patients of the cancer risks of its diabetes drug Actos. Then it and Eli Lilly were hit with a breathtaking $9 billion verdict a year later. Now Takeda is looking to extricate itself from the more than 8,000 lawsuits in the U.S. with a $2.2 billion settlement.

Parexel buys an Indian CRO with an eye on drug safety

CRO giant Parexel International is acquiring an Indian company devoted to pharmacovigilance, looking to expand its share of the global market for managing drug safety data.

Emerging markets tipped to push drug safety software market past $150M

Analysts at MarketsandMarkets have looked into their crystal ball and come up with a forecast of the pharmacovigilance and drug safety software sector. The authors predict the value of the market will top $150 million by 2019, with Asia and Latin America tipped to be the driving forces behind growth over the next few years.

Critics say White House plan to combat antibiotic resistance falls 'woefully short'

The Obama Administration rolled out its 5-year plan to combat antibiotic-resistant bacteria on Thursday, and it was met with widespread disdain from critics who say it doesn't do enough to prevent livestock producers from using the drugs in ways that endanger both animal and human health.

Geriatrics experts call for halt to Low-T consumer ads

A couple of geriatrics experts have joined the chorus of recommendations against testosterone therapy. But they're going a step further. They say drugmakers' enthusiastic advertising--which happened to be effective, too--was actually disease-mongering.

FDA lets Lilly's long-acting Zyprexa off the hook in patient deaths

The FDA says it won't recommend new limits on Eli Lilly schizophrenia med Zyprexa Relprevv after almost a year of investigating the deaths of two patients 3 to 4 days after they received injections.

Jury: Boy didn't prove J&J drug caused his breast growth

Johnson & Johnson won a split decision in Philadelphia court Friday, in the latest Risperdal lawsuit to go to trial. A jury decided that J&J did fail to warn doctors that the antipsychotic drug could cause breast development in boys, Reuters reports.

Gilead warns of fatal reaction to Sovaldi, Harvoni and heart drug

Gilead Sciences' superselling hepatitis C drugs have hit a speed bump after 9 patients taking either Harvoni or Sovaldi, as well as a common drug for heart arrhythmias, had serious reactions. One of the 9 had a heart attack and died. Three others had to receive pacemakers.

FDA hustles on opioid guidance to avoid budget meddling

The FDA is rushing to complete guidance on abuse-deterrent opioids before the end of June because if it doesn't, Congress has promised to take away $20 million in money for salaries and expenses in the FDA Commissioner's Office and give it instead to its criminal investigations unit to fight drug diversion.